An interview with:
Yelena Y Janjigian MD, Medical Oncologist, Chief of Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York.
CHICAGO, USA—Patients with early-stage solid cancers with DNA mismatch repair-deficiency (also known as microsatellite instability) benefitted greatly if they received anti-programmed death-1 (PD-1) immunotherapy with pembrolizumab after surgery and standard of care if they tested positive for circulating tumor DNA (ctDNA).
These findings come from a phase two clinical trial reported at the 2025 Annual Meeting of the American Association for Cancer Research. Audio Journal of Oncology correspondent Peter Goodwin talked with first author of the study: Yelena Y Janjigian MD, Chief of the Gastrointestinal Oncology Service at Memorial Sloan-Kettering Cancer Center in New York.
INTERVIEW: Yelena Y Janjigian, MD
AACR ABSTRACT Title:
Circulating tumor DNA status to direct adjuvant immunotherapy for mismatch repair deficient tumors
